INDP
Indaptus Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.59M
P/E Ratio
—
EPS
$-21.58
Beta
0.99
52W High
$19.91
52W Low
$1.51
50-Day MA
$1.90
200-Day MA
$4.34
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Indaptus Therapeutics Inc
Indaptus Therapeutics Inc. is an innovative biotechnology company specializing in the development of advanced immunotherapies designed to revolutionize cancer treatment. Leveraging a proprietary platform to amplify the immune system's ability to recognize and eliminate tumor cells, the company is poised to enhance treatment efficacy and improve patient outcomes. With a diverse portfolio of clinical candidates targeting significant unmet medical needs in oncology, Indaptus positions itself strategically for growth in a competitive market. Its commitment to scientific excellence and collaboration with prestigious research institutions underscores its potential to become a transformative leader in the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.83M |
| Operating Margin | 0.00% |
| Return on Equity | -588.00% |
| Return on Assets | -148.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.45 |
| Price-to-Book | 1.14 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.24M |
| Float | $1.18M |
| % Insiders | 37.17% |
| % Institutions | 4.09% |
Data last updated: 4/8/2026